Syndax Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 33.79K shares.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 188.71K shares, a 78.57% decline year-over-year.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 163.04K shares, a 36.74% decline year-over-year.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 276.51K shares, a 858.79% increase year-over-year.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.14M shares, a 58.34% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 717.41K shares, a 8.36% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 662.04K shares, a 50926207.69% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.30 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 1.14M shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 717.41K shares 10-K · filed 2026-02-26 | |
| 2023-12-31 | 33.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 662.04K shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 188.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -539.04K shares derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | 163.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 152.97K shares derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | 276.51K shares 10-Q · filed 2023-05-08 | 247.67K shares derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -1.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 1.30 shares 10-K · filed 2025-03-03 |
| 2022-09-30 | 880.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 1.59M shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 257.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 937.60K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 28.84K shares 10-Q · filed 2023-05-08 | 770.31K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 427.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 842.42K shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 223.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 858.10K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 90.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 805.07K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 100.95K shares 10-Q · filed 2022-05-09 | 805.09K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 443.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 755.17K shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 170.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 311.87K shares derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | 90.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 145.18K shares derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | 51.03K shares 10-Q · filed 2021-05-11 | 76.89K shares derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 25.86K shares 10-K · filed 2022-03-01 |
| 2019-09-30 | 3.69K shares 10-Q · filed 2019-11-07 | 25.86K shares derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | 22.17K shares 10-Q · filed 2019-08-07 | 22.17K shares derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-07 | 7.85K shares derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | 7.85K shares 10-K · filed 2021-03-12 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-07 | 7.95K shares derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | 7.85K shares 10-Q · filed 2019-08-07 | 8.60K shares derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-08 | 18.48K shares derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | 103.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | 46.68K shares 10-K · filed 2020-03-05 |
| 2017-09-30 | 647.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | |
| 2017-06-30 | 17.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | |
| 2017-03-31 | 28.20K shares 10-Q · filed 2017-05-09 | |
| 2016-12-31 | 441.57K shares 10-K · filed 2019-03-07 | |
| 2015-12-31 | 41.61K shares 10-K · filed 2018-03-08 | |
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |